Format
Sort by

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 78539

1.

Independent of Cirrhosis, Hepatocellular Carcinoma risk is increased with Diabetes and Metabolic Syndrome: A retrospective cohort study.

Kasmari A, Welch A, Liu G, Leslie D, McGarrity T, Riley T.

Am J Med. 2017 Jan 18. pii: S0002-9343(17)30034-7. doi: 10.1016/j.amjmed.2016.12.029. [Epub ahead of print]

PMID:
28109969
2.

Hepatitis C virus reactivation due to antiemetic steroid therapy during treatment of hepatocellular carcinoma.

Kawano Y, Miyanishi K, Takahashi S, Kubo T, Ishikawa K, Sugita S, Takada K, Kobune M, Hasegawa T, Kato J.

J Infect Chemother. 2017 Jan 18. pii: S1341-321X(16)30274-4. doi: 10.1016/j.jiac.2016.12.008. [Epub ahead of print]

PMID:
28109738
3.

Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt.

Youssef NF, El Kassas M, Farag A, Shepherd A.

BMC Gastroenterol. 2017 Jan 21;17(1):18. doi: 10.1186/s12876-017-0581-1.

PMID:
28109264
4.

Treatment of Hepatitis C Virus Infection in Children: Time for Action.

Indolfi G, D'Antiga L.

Liver Transpl. 2017 Jan 20. doi: 10.1002/lt.24727. [Epub ahead of print] No abstract available.

PMID:
28109055
5.

ITPA polymorphism correlates with the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.

Kozuka R, Hai H, Teranishi Y, Motoyama H, Kawamura E, Hagihara A, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y, Kawada N, Tamori A.

J Gastroenterol Hepatol. 2017 Jan 20. doi: 10.1111/jgh.13743. [Epub ahead of print]

PMID:
28109022
6.

The MBOAT7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B.

Thabet K, Chan HL, Petta S, Mangia A, Berg T, Boonstra A, Brouwer WP, Abate ML, Wong VW, Nazmy M, Fischer J, Liddle C, George J, Eslam M.

Hepatology. 2017 Jan 20. doi: 10.1002/hep.29064. [Epub ahead of print]

PMID:
28109005
7.

Eradication of HCV and non-liver-related non-AIDS-related events in HIV/HCV coinfection.

Berenguer J, Rodríguez-Castellano E, Carrero A, Von Wichmann MA, Montero M, Galindo MJ, Mallolas J, Crespo M, Téllez MJ, Quereda C, Sanz J, Barros C, Tural C, Santos I, Pulido F, Guardiola JM, Rubio R, Ortega E, Montes ML, Jusdado JJ, Gaspar G, Esteban H, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group..

Hepatology. 2017 Jan 21. doi: 10.1002/hep.29071. [Epub ahead of print]

PMID:
28109003
8.

Reply to "Addressing opioid use disorder in modeling hepatitis C transmission among persons who inject drugs".

Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Dhersin JS, Yazdanpanah Y.

Hepatology. 2017 Jan 21. doi: 10.1002/hep.29069. [Epub ahead of print] No abstract available.

PMID:
28108986
9.

Addressing opioid use disorder in modeling hepatitis C transmission among persons who inject drugs.

Smith J, Rich J.

Hepatology. 2017 Jan 21. doi: 10.1002/hep.29070. [Epub ahead of print] No abstract available.

PMID:
28108982
10.

Against the Odds: Syringe Exchange Policy Implementation in Indiana.

Meyerson BE, Lawrence CA, Miller L, Gillespie A, Raymond D, Kelley K, Shannon DJ.

AIDS Behav. 2017 Jan 20. doi: 10.1007/s10461-017-1688-7. [Epub ahead of print]

PMID:
28108875
11.

Paired assessment of liver telomere lengths in hepatocellular cancer is a reliable predictor of disease persistence.

Feng WD, Yu DC, Shi XB, Li BH, Luo OY, Yan C, Ding YT.

Biosci Rep. 2017 Jan 20. pii: BSR20160621. doi: 10.1042/BSR20160621. [Epub ahead of print]

PMID:
28108675
12.

NS5A Resistance-Associated Substitutions in Patients with Genotype 1 Hepatitis C Virus: Prevalence and Effect on Treatment Outcome.

Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R, Svarovskaia E, Dvory-Sobol H, Doehle B, Hedskog C, Yun C, Brainard DM, Knox S, McHutchison JG, Miller MD, Mo H, Chuang WL, Jacobson I, Dore GJ, Sulkowski M.

J Hepatol. 2017 Jan 17. pii: S0168-8278(17)30011-9. doi: 10.1016/j.jhep.2017.01.007. [Epub ahead of print]

PMID:
28108232
13.

Pharmaceutical opioid use among oral and intravenous users in Australia: A qualitative comparative study.

Dertadian G, Iversen J, Dixon TC, Sotiropoulos K, Maher L.

Int J Drug Policy. 2017 Jan 17;41:51-58. doi: 10.1016/j.drugpo.2016.12.007. [Epub ahead of print]

PMID:
28107670
14.

Variant outcomes of liver transplantation for hepatitis C virus patients in different age categories: Impact of the MELD score.

Hu Z, Zhou J, Li Z, Xiang J, Zhang Q, Yan S, Wu J, Zhang M, Wang W, Zheng S.

J Hepatobiliary Pancreat Sci. 2017 Jan 20. doi: 10.1002/jhbp.435. [Epub ahead of print]

PMID:
28107613
15.

Epidemiology update for Hepatitis C Virus and Hepatitis B Virus in End Stage Renal Disease in France (Réseau Epidémiologique et Information en Néphrologie registry).

Isnard Bagnis C, Couchoud C, Bowens M, Sarraj A, Deray G, Tourret J, Cacoub P, Tezenas du Montcel S.

Liver Int. 2017 Jan 20. doi: 10.1111/liv.13367. [Epub ahead of print]

PMID:
28107607
16.

Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: Is elimination possible in a high prevalence setting?

Gountas I, Sypsa V, Anagnostou O, Martin NK, Vickerman P, Kafetzopoulos E, Hatzakis A.

Addiction. 2017 Jan 20. doi: 10.1111/add.13764. [Epub ahead of print]

PMID:
28107585
17.

Chronic Hepatitis C and Chronic Kidney disease: Advances, Limitations and Unchartered Territories.

Mendizabal M, Reddy KR.

J Viral Hepat. 2017 Jan 20. doi: 10.1111/jvh.12681. [Epub ahead of print]

PMID:
28107583
18.

Correction: Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon.

Gambato M, Caro-Pérez N, González P, Cañete N, Mariño Z, Lens S, Bonacci M, Bartres C, Sánchez-Tapias JM, Carrión JA, Forns X, Juan M, Pérez-Del-Pulgar S, Londoño MC.

PLoS One. 2017 Jan 20;12(1):e0170913. doi: 10.1371/journal.pone.0170913.

19.

Nonstructural 5A Protein of Hepatitis C Virus Interferes with Toll-Like Receptor Signaling and Suppresses the Interferon Response in Mouse Liver.

Tsutsumi T, Okushin K, Enooku K, Fujinaga H, Moriya K, Yotsuyanagi H, Aizaki H, Suzuki T, Matsuura Y, Koike K.

PLoS One. 2017 Jan 20;12(1):e0170461. doi: 10.1371/journal.pone.0170461.

20.

High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments.

Nien HC, Hsu SJ, Su TH, Yang PJ, Sheu JC, Wang JT, Chow LP, Chen CL, Kao JH, Yang WS.

PLoS One. 2017 Jan 20;12(1):e0170028. doi: 10.1371/journal.pone.0170028.

Items per page

Supplemental Content

Loading ...
Support Center